ication is administered continuously, this process is maximized. Higher doses may be justified in severe bronchoconstriction as it is likely that a smaller percentage of inhaled medication reaches the 3-adrenergic receptors in this setting.
High-dose, continuously administered nebulized albuterol has been shown to be safe and effective in children.2 Recent studies have compared the effect of continuous vs intermittent delivery of albuterol in adults presenting with acute asthma using different doses of albuterol.35 Superiority of continuous delivery was demonstrable only in poststudy subgroup analysis in patients who had more severe asthma.45 We sought to examine both the dosage ofalbuterol used for nebulization and the method of delivery, either continuously or intermittently, prospectively in ED patients who presented with an FEV, of less than 40% of predicted.
MATERIALS AND METHODS
The study was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center. Patients were recruited from the ED of Parkland Memorial Hospital by the treating physician if they met the following entry criteria: (1) a diagnosis of acute asthma;6 (2) an initial FEV1 of less than 40% of predicted; (3) development of asthma at an age younger than 45 Clinical Investigations Adult patients suffering from acute asthma presenting to the Emergency Department with an FEV1 of less than 40% of predicted were randomized into four treatment groups. They were treated with nebulized albuterol at a high (7.5 mg) or standard (2.5 mg) dose given either continuously through 1 h, or intermittently every hour, for 2 h. When the FEV1 improvements for the different groups at 2 h were compared, the groups treated with continuous nebulization had the greatest improvement. The improvements (1.07 L for the high-dose group, and 1.02 L for the standard-dose group) were significantly greater than the improvement seen with standard-dose intermittent treatment (0.72 L; p<0.05). The improvement in FEV1 of the high-dose, hourly treated group was intermediate in magnitude between these (0.90 L). There was no difference in the improvement seen between the two groups treated with continuous nebulization. The potassium fall, present in all groups, was more pronounced in the groups treated with high doses of albuterol. Only one person (high dose, continuous treatment group) developed hypokalemia of less than 3.0 mmol/L. The high-dose hourly treated group had the highest incidence of side effects, and the standard-dose continuously treated group had the lowest. The standard-dose continuous-treatment regimen had the greatest improvement in FEV1 with the least number of side effects.
(CHEST 1996; 110:42-47) 3 .0 mL ofsolution was used at an airflow rate of6 Jimin. Thus, 15.0 mL was required for 1 h ofcontinuous nebulization. For group A, 7.5 mg (1.5 mL) was diluted with 13.5 mL normal saline solution (NSS). For group B, 2.5 mg (0.5 mL) was diluted with 14.5 mL NSS. For these continuous treatment groups, the nebulization canister (capacity of 5 mL) was refilled as needed. For the hourly treatment groups, the albuterol was diluted to constitute 3 mL of solution. For group C, 7.5 mg (1.5 mL) was diluted with 1.5 mL of NSS (1:1 dilution), and for group D, 2.5 mg (0.5 mL) was diluted with 2.5 mL of NSS (standard 1:5 dilution).
Albuterol solution for each group was prediluted and placed in bottles marked A, B, C, or D. Other than that A and B were to be given continuously and C and D hourly, neither the investigator, the therapist, or the patient knew which bottle corresponded with which treatment group. Nebulization treatments were given by a registered respiratory therapist using disposable reservoirs and mouthpieces that generate particles 1.45 All patients were placed on a cardiac monitor. BP, pulse, respiratory rate, and pulse oximetry measurements were monitored every 15 min. An ECG and electrolyte determination were done prior to and after 2 h of albuterol treatment. All received methylprednisolone (Solumedrol), 125 mg IV, and a tapering dose of prednisone on hospital discharge. Other diagnostic tests were at the discretion of the treating physician. Patients were treated for 2 h on the study protocol. After this time, the need for additional treatment was determined by the patient's treating physician.
Every 15 min, the patients were asked if they experienced any side effects. The side effects were graded on a four-level descriptive scale of (1) 
RESULTS
The four groups were similar in terms of demographics, vital signs, and severity of disease (Table 1) . Figure 1 shows the progression of FEV1 values for the four groups with treatment. The changes in FEV1 and percent predicted FEV1 with treatment are shown in Table 2 . After the first hour of nebulization therapy, the improvement in FEV1 was greatest for the two continuously treated groups. The improvement seen in these two groups was indistinguishable. The standarddose intermittent treatment group showed the least improvement in FEV1, but still improved by more than 50%. Each group showed a highly significant improvement. Comparisons between groups showed that the overall difference in improvement was statistically significant at ap value of <0.05. Individual comparisons showed both continuous-treatment groups to have improved significantly greater than did the standarddose hourly group (p<0.05). The improvement in FEV1 of the high-dose hourly group was not statistically different from that of either of the continuously treated groups or from that ofthe standard-dose hourly group.
During the second hour of treatment, all of the treatment groups continued to improve at approximately the same rate ( Table 2 ). The FEV1 values at the end of 2 h for all of the groups were approximately 20% greater than they had been at the end of 1 h of treatment. Improvement within each group continued to be significant.
After 2 h of therapy, the differences in FEV1 improvement overall were statistically significant (p<0.05, Table 2 ). As after the first hour, the comparisons between each of the continuously treated groups and the standard-dose intermittent group were the ones that were statistically significant. For all of the groups, most of the 2-h improvement in FEV1 (65 to 75%) occurred during the first hour of treatment.
Comparing the two hourly treatment groups, the improvement in FEV1 immediately after the first treatment was substantial for each group, and constituted most of the total FEV1 improvement at 2 h (Table 3). The high-dose group improved by slightly more than did the standard-dose group (0.51 L vs 0.46 L), but this was not statistically significant. During the wait till the second treatment, the FEV1 of the high-dose group improved by a small amount, 0.14 L or by 9.8%, which was significantly more than the improvement in the standard-dose group (p<0.05). There was no difference in FEV1 improvements after the second hourly dose.
Potassium levels were drawn before and after 2 h of treatment in all patients. They decreased in all treatment groups. The greatest decrease was seen in the high-dose continuously treated group followed by the high-dose intermittent group, then the standard-dose continuous group, and the standard-dose intermittently treated group (Table 4) . The overall changes were statistically significant for each group, but the differences among groups was not.
Ofthe 165 patients entered, only 1 patient, who had been given high-dose continuous treatment, developed hypokalemia less than 3.0 mEq/L. The pretreatment serum potassium level of 4.5 fell to 2.8 after 2 h. There were no ECG changes. The patient did have a very good bronchodilator response, as her FEV1 improved from 0.70 L to 2.17 L. She was given 40 mEq orally and 40 mEq KCI IV (over 2 h). Repeated serum potassium level was 3.5 mEq/L. She remained asymptomatic from the hypokalemia and was discharged from the hospital.
The changes in BPs, pulse rates, respiratory rates, and room air oxygen saturations were variable. The mean values for these variables changed by only slight amounts, and differences were not statistically significant among groups.
Twenty-eight percent ofthe enrolled patients had at least one side effect. Most of these (41%) were in the high-dose hourly treatment group (p=0.14). The most common side effect was "tremor," which was experienced by 14% of all entered patients. The patients in the high-dose groups experienced significantly more tremor than those in the standard-dose groups: 24% in the high-dose hourly group and 20% in the high-dose continuous group, compared with 9.3% in the standard-dose hourly group and only 2.5% in low-dose continuous group (p<0.05). The vast majority of side effects were graded as "noticeable" (lowest severity grade) by the patients. The difference in incidence of total side effects among the four groups was not significant. None of the side effects were graded as intolerable.
DISCUSSION
High-dose (7.5 mg) albuterol delivered continuously over each hour is similar to the National Heart Lung and Blood Institute Expert Panel's recommended initial treatment of acute asthma of three 2.5-mg nebulization treatments over the course of 1 or 1.5 h.' Surprisingly, the effect of this treatment was matched by the improvement in FEV1 seen with the standard-dose (2.5 mg) albuterol treatment diluted to last an hour. Both continuously treated groups improved their FEV1 values by approximately 90% after the first hour and by 128% by the second hour. The very dilute mixture of albuterol used in the standard-dose continuous group (0.5 mL, or 2.5 mg, in 14.5 mL saline solution, ie, a 1:29 ratio) was able to bronchodilate as effectively as a solution three times as concentrated, if administered continuously.
The improvement in the FEV1 of patients given single, hourly nebulized treatments of standard-dose (2.5 mg) albuterol was less than that seen with either of the continuously treated groups (p<0.05). After 1 h, the absolute magnitude of the difference in improve- h were small and not statistically significant. Immediately after the first treatment, the high-dose intermittent group improved it's mean FEV1 only slightly more (0.51 L vs 0.46 L, or by 0.05 L) than did the standarddose group. The difference was not statistically significant. After the second treatment, the standard-dose group actually improved by a nonsignificant small amount more than the high-dose hourly group. The only statistically significant difference was that during the wait between the first and second treatments, the high-dose group improved by slightly more than did the standard-dose group (0.14 L vs 0.03 L; p<0.05).
There was no such difference during the wait after the second treatment. If there is any benefit from the use of a concentrated single treatment, it would seem that it would be with the initial treatment only.
The side effects encountered were not serious and did not require discontinuation of treatment. The difference in the incidence of tremor was the only comparison that was statistically significant overall. Side effect profiles may be important in individual patients with specific comorbid conditions. In such cases, the current data support using the standard low-dose continuously nebulized albuterol.
The effect on potassium was dose dependant with a slightly greater decrease in patients getting the continuous delivery of the same dose of albuterol. The incidence of hypokalemia of less than 3.0 mEq/L was rare, as it occurred only once (in the high-dose continuously treated group) and was easily corrected without any adverse effect. It may be wise to check potassium levels in patients getting prolonged treatment with high doses of albuterol. A previous study using 2.5 mg of albuterol nebulized every half hour showed a higher incidence of hypokalemia.8
The effect on the BP, pulse, and respiratory rate was inconsistent. Previous reports have noted that, in general, BP and pulse tend to decrease with relief of bronchospasm.9 There was no clear pattern that developed. Some patients obtained relief of bronchospasm and had normalization in BP and pulse, and others had increases in BP and pulse most likely from the 3-adrenergic effects of the medication.
In adults with acute asthma, there have been a few previous reports that have studied continuous vs intermittent delivery of albuterol. Colacone et al3 shoxved no difference between the effect of 5 mg albuterol given every hour for 2 h and 5 mg given continuously through each hour for 2 h. Two later studies suggested that continuous albuterol resulted in greater improvements as opposed to intermittent albuterol in patients with more severe bronchoconstriction. Rudnitsky et a14 treated patients with either 2.5 mg albuterol every 30 min or, after the initial dose of 2.5 mg, 10 mg over 2 h. Overall there was no significant difference in peak flows after 2 h; however, when subgroup analysis was done, patients who presented with peak flows of less than 200 Umin did better by approximately 50 Umin (119% improvement vs 78% improvement).4 Lin et a15 used very high doses of albuterol, administering 30 mg over 110 min either continuously or in 5-mg treatments every 20 min, twice the dose of the high dose in the current study. Again, there was no overall significant difference in FEV1, but the authors were able to statistically show there was a higher rate of improvement in patients who presented with an FEV1 ofless than 50% ofpredicted. 5 The above three studies all used different doses of albuterol on asthma patients with different severities of bronchoconstriction. We undertook the current study design with four treatment groups to control for both the method of nebulized albuterol administration and the dosage used. The presenting FEV1 was lower in the current group of patients in an effort to test the hypothesis that continuously delivered albuterol results in a greater degree of bronchodilation in especially sick patients with acute asthma, as had been suggested by the previous studies.
To our knowledge, low-dose continuous nebulization has not been systematically studied previously. A recent retrospective, uncontrolled report on a limited number of pediatric patients documents safety and effectiveness.'0 Our data suggest that it may be the optimal treatment in terms of most rapid improvement in bronchoconstriction with the least side effects. For those with concomitant coronary artery disease or another comorbid condition possibly made worse with high doses of ,3-agonist, low-dose continuous nebulization may prove to be the best choice.
Though the current study focuses on treatment of acute asthma with 13-agonists, anti-inflammatory medication is an irreplaceable component of therapy. In all groups, anti-inflammatory treatment was begun early with the use of methylprednisolone, 125 mg IV at the outset of therapy, and continued after ED, discharge with a tapering dose of oral prednisone.
In conclusion, for the patient population studied (FEVI<40% predicted, but not requiring assisted ventilation), continuous delivery of albuterol at high (7.5 mg/h) or standard doses (2.5 mg/h) is superior to hourly treatment with the standard 2.5 mg during the first hours oftherapy. There was no difference in FEV, improvements between the two doses used for continuous treatment, but the standard dose had fewer side effects. The high-dose intermitent-treatment regimen is intermediate in effectiveness and has a lingering effect after initial treatment not seen after the initial standard dose treatment. After the first hour, all groups improved at the same rate.
